Labetalol for the treatment of hypertension in pregnancy. Pharmacokinetics and effects on the uteroplacental blood flow.
Plasma levels of labetalol were measured in 7 hypertensive pregnant women who were given 200 mg three times daily orally. The plasma concentrations were usually lower than those reported in the non-pregnant state at a comparative dose. In 5 women the ratio between fetal and maternal plasma labetalol concentrations could be calculated at parturition. The median value of this quotient was about 50%. The effect of labetalol 1 mg/kg body weight intravenously was registered with functional placental scintigraphy. Fifteen women participated. A computer-linked gamma camera above the uterus registered the radioactivity in the placental region after two intravenous bolus injections of 18.5 MBq indium-113m chloride. From the radioactivity uptake curves, uteroplacental blood flow indices could be calculated before and 30 minutes after the labetalol injection. Despite a significant reduction in maternal blood pressure, no change in uteroplacental blood flow index was found. This could indicate that the vascular resistance in the maternal placental circulation was reduced by labetalol.
D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D007700:Kinetics; D007741:Labetalol / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D010920:Placenta / Q000098:blood supply*; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D012039:Regional Blood Flow / Q000187:drug effects; D014599:Uterus / Q000098:blood supply*
D004983:Ethanolamines; D007741:Labetalol